Biorez was issued four key utility patents by the United States Patent and Trademark Office between July and September 2021.
The four patents relate to Biorez’s proprietary BioBrace Implant, a biocomposite soft tissue scaffold intended to reinforce soft tissue repair, and act as a biologic scaffold to promote healing.
BioBrace was cleared by FDA in April and is indicated for the reinforcement of soft tissue where weakness exists.
Unlike traditional implant materials that are either synthetic or biologic in origin, BioBrace is a composite of both. Its architecture features a highly porous type I collagen matrix reinforced with bioresorbable PLLA microfilaments. The unique design of the BioBrace enables the mechanical reinforcement of soft tissue repairs, with a bio-inductive scaffold to promote healing.
These recent patent issuances provide protection for the Biorez BioBrace implant and its use in surgery into 2040, and expand Biorez’s patent portfolio to eight issued US patents, and 16 outside the U.S. Additional U.S. and foreign patent applications are pending.
Recently issued Biorez patents, uniformly titled Composite scaffold for the repair, reconstruction, and regeneration of soft tissues:
- US Patent Number: 11,058,532 (Granted 7/13/2021)
- US Patent Number: 11,065,102 (Granted 7/20/2021)
- US Patent Number: 11,096,776 (Granted 8/24/2021)
- US Patent Number: 11,116,622 (Granted 9/14/2021)
Source: Biorez Inc.